Procter Gamble Health Ltd vs Remus Pharmaceuticals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 03, 2026

Key Highlights

The Latest Trading Price of Procter & Gamble Health Ltd is ₹ 5194 as of 30 Apr 15:30 . The P/E Ratio of Procter & Gamble Health Ltd is 0 as of March 2024 .The P/E Ratio of Remus Pharmaceuticals Ltd is 49.4 as of March 2024 . The Market Cap of Procter & Gamble Health Ltd is ₹ 0 crore as of March 2024 .The Market Cap of Remus Pharmaceuticals Ltd is ₹ 1016 crore as of March 2024 . The revenue of Procter & Gamble Health Ltd for the Sep '25 is ₹ 329.87 crore as compare to the Jun '25 revenue of ₹ 342.77 crore. This represent the decline of -3.76% The revenue of Remus Pharmaceuticals Ltd for the Sep '25 is ₹ 0 crore as compare to the Jun '25 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Procter & Gamble Health Ltd for the Sep '25 is ₹ 125.22 crore as compare to the Jun '25 ebitda of ₹ 94.37 crore. This represent the growth of 32.69% The ebitda of Remus Pharmaceuticals Ltd for the Sep '25 is ₹ 0 crore as compare to the Jun '25 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of Procter & Gamble Health Ltd changed from ₹ 46.56 crore to ₹ 88.54 crore over 6 quarters. This represents a CAGR of 53.49% The net profit of Remus Pharmaceuticals Ltd changed from ₹ 0 crore to ₹ 0 crore over 6 quarters. This represents a CAGR of 0.0% The dividend payout of Procter & Gamble Health Ltd changed from 122.06 % to 0 % over 9 quarters. This represents a CAGR of -100.00% The dividend payout of Remus Pharmaceuticals Ltd changed from 4.44 % to 5.31 % over 5 quarters. This represents a CAGR of 15.39% .

About Procter & Gamble Health Ltd

Procter & Gamble Health Limited was erstwhile incorporated as E Merck (India) Limited in 1967.
The Company's name was changed from E Merck (India) Limited to Merck Limited on March 27, 2002.
Later, the name of the Company was changed to Procter & Gamble Health Limited on 6 May, 2019.
The company was set up to take over the business of the Indian branch of Emeda Exports with all their assets and liabilities.
The company is a 51% subsidiary of German firm Merck KGaA, is a leading player in vitamin formulations. Procter & Gamble Health Limited is an Indian-based company principally engaged in the business of manufacturing and marketing of pharmaceuticals and chemicals.

About Remus Pharmaceuticals Ltd

Remus Pharmaceuticals Limited was originally incorporated as Remus Pharmaceuticals Private Limited' as a Private Limited Company, vide Certificate of Incorporation dated September 21, 2015, issued by the Assistant Registrar of Companies, Gujarat.
Subsequently, Company converted from a Private to Public and the name of the Company was changed to 'Remus Pharmaceuticals Limited' on January 06, 2023 by the Registrar of Companies, Ahmedabad. The Company is engaged in marketing & distribution of finished formulations of pharmaceutical drugs.
It deals in API (Active Pharmaceutical Ingredient), provide technical consultancy services to various distributors for preparation of reports on the dossiers of the products to be registered by them in various countries.
The Company deal in drug forms like Capsules, Cream, Eye Drops, Gel, Infusion, Inhalation, Inhaler, Injection, Nail Lacquer, Nasal Solution, Nasal Spray, Nebuliser, Ointment, Ophthalmic, Oral Gel, Oral Solution, Oral Suspension, Sachet, Suspension, Tablet.

FAQs for the comparison of Procter & Gamble Health Ltd and Remus Pharmaceuticals Ltd

Which company has a larger market capitalization, Procter & Gamble Health Ltd or Remus Pharmaceuticals Ltd?

Market cap of Procter & Gamble Health Ltd is 8,622 Cr while Market cap of Remus Pharmaceuticals Ltd is 807 Cr

What are the key factors driving the stock performance of Procter & Gamble Health Ltd and Remus Pharmaceuticals Ltd?

The stock performance of Procter & Gamble Health Ltd and Remus Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Procter & Gamble Health Ltd and Remus Pharmaceuticals Ltd?

As of May 3, 2026, the Procter & Gamble Health Ltd stock price is INR ₹5194.55. On the other hand, Remus Pharmaceuticals Ltd stock price is INR ₹685.3.

How do dividend payouts of Procter & Gamble Health Ltd and Remus Pharmaceuticals Ltd compare?

To compare the dividend payouts of Procter & Gamble Health Ltd and Remus Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.